Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999122 · ClinicalTrials.gov registry record
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
A clinical trial of Stroke and Hemorrhagic Stroke, sponsored by EMVision Medical Devices.
- Recruiting
- Registry status
- 300
- Enrollment target
- 4
- Study locations
NCT06999122: Recruiting study of Stroke and Hemorrhagic Stroke, sponsored by EMVision Medical Devices.
NCT06999122 is a study of Stroke and Hemorrhagic Stroke that is actively recruiting participants, run by EMVision Medical Devices. The registered enrollment target is 300 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999122, a study of Stroke and Hemorrhagic Stroke, is actively recruiting participants, sponsored by EMVision Medical Devices.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available. EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Brain Scan
Study Locations (4)
Florida
- Mayo Jacksonville - Jacksonville
Texas
- UTHealth - Houston
New South Wales
- Liverpool Hospital - Liverpool
Victoria
- Royal Melbourne Hospital - Parkville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2026-11-28 |
What NCT06999122 shows while recruiting
NCT06999122 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Brain Scan is the first listed.
NCT06999122 reports a single indexed study location in Florida, Texas, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06999122 about?
NCT06999122 is a clinical study titled "Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients". The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain ...
What is the current status of trial NCT06999122?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-03-26. Estimated completion is 2026-11-28.
What conditions does trial NCT06999122 study?
This clinical trial studies the following conditions: Stroke, Hemorrhagic Stroke.
What interventions are being tested in trial NCT06999122?
The interventions under investigation include: Brain Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06999122?
This trial is sponsored by EMVision Medical Devices, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999122 being conducted?
This trial has 4 study locations across Florida, Texas, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06999122's enrollment target sits among peer trials
300 75th of 454 higher than 377 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
RECRUITING
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
RECRUITING
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI